RxDoctor Payments Data

Jill Frickenhaus, NP

Nurse Practitioner · New York, NYNPI 1346466752

Payments from drug & device makers

$2,213in general payments, 2019–2025

Across 112 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$412
  • Janssen Products, LP$135
  • Johnson & Johnson$15

What the payments were for

  • Food & beverage$2,07894%
  • Education$1356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,213 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$31,598
Medicare patients
154
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala383$1,598,890
JulucaDolutegravir/Rilpivirine212$786,187
GenvoyaElviteg/Cob/Emtri/Tenof Alafen193$764,168
DescovyEmtricitabine/Tenofov Alafenam247$572,717
TivicayDolutegravir Sodium217$555,136
TriumeqAbacavir/Dolutegravir/Lamivudi119$526,944
DovatoDolutegravir Sodium/Lamivudine163$524,483
IsentressRaltegravir Potassium193$419,798
OdefseyEmtricitab/Rilpiviri/Tenof Ala31$127,410
PrezcobixDarunavir/Cobicistat40$98,883
EdurantRilpivirine Hcl48$75,920
EliquisApixaban59$59,354
Etravirine43$48,698
SelzentryMaraviroc28$47,160
PifeltroDoravirine22$41,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Viread$1,651$2,949,538834 claims
Viiv Healthcare CompanyJuluca, Tivicay, Triumeq, Dovato$412$2,392,750711 claims
Johnson & JohnsonPrezcobix$15$98,88340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →